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ABSTRACT (246/250 words) 
Multiplex Ligation-dependent Probe Amplification (MLPA) has become available for the 
detection of a large deletion on the MECP2 gene allowing genetic confirmation of previously 
unconfirmed cases of clinical Rett syndrome. This study describes the phenotype of those 
with a large deletion and compares to those with other pathogenic MECP2 mutations. 
Individuals were ascertained from the Australian Rett Syndrome and InterRett databases with 
data sourced from family and clinician questionnaires, and two case studies were constructed 
from the longitudinal Australian data. Regression and survival analysis were used to compare 
severity and age of onset of symptoms in those with and without a large deletion. Data were 
available for 974 individuals including 51 with a large deletion and ages ranged from 1 year 4 
months months to 49 years (median 9 years). Those with a large deletion were more severely 
affected than those with other mutation types. Specifically, individuals with large deletions 
were less likely to have learned to walk (OR 0.42, 95%CI 0.22-0.79, p=0.007) and to be 
currently walking (OR 0.53, 95%CI 0.26-1.10, p=0..089), and were at higher odds of being in 
the most severe category of gross motor function (OR 1.84, 95%CI 0.98-3.48, p=0.057) and 
epilepsy (OR 2.72, 95%CI 1.38-5.37, p=0.004). They also developed epilepsy, scoliosis, 
hand stereotypies and abnormal breathing patterns at an earlier age. We have described the 
disorder profile associated with a large deletion from the largest sample to date and have 
found that the phenotype is severe with motor skills particularly affected.   
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Rett syndrome is a severe neurodevelopmental disorder which is clinically diagnosed [1] and 
usually associated with a mutation in the MECP2 gene.[2] The first line of genetic testing 
involves mutation screening and sequencing of exons 3 and 4 for small sequence changes.[3] 
Over 200 MECP2 mutations have been identified[4] with some point mutations (p.R106W, 
p.R133C, p.R168X, p.R255X, p.R270X, p.R294X, p.R306C and p.T158M) occurring more 
commonly. Subsequent to sequencing, Multiplex Ligation-dependent Probe Amplification 
(MLPA) has also became available for the detection of deletions of one or more exons.[5] 
Archer et al.[6] found that many of the large deletions had a breakpoint in the deletion prone 
region of exon 4 and were of variable size. Used as a complementary method to DNA 
sequencing, MLPA now allows for the identification of a pathogenic MECP2 mutation in the 
group of females with a clinical presentation of Rett syndrome in whom a pathogenic MECP2 
mutation would not previously have been identified. 
 
Both classic and atypical presentations have been reported in those with large deletions [6, 7, 
8] but these studies have had relatively few cases (n=12-22) or have not included a 
comparison group of individuals with other types of mutations. Larger studies have 
confirmed that a large deletion is associated with a severe phenotype, for example, in 
comparison with the phenotype of cases with the p.R133C [9] or a C-terminal deletion [10] 
which are both considered to be generally mild. Examination of a large sample of individuals 
with a large deletion in terms of general severity and the specific aspects of phenotype is 
needed to advance our understanding of this more recently identified mutation group.   
 
Combining data collected as part of InterRett,[11] an international Rett syndrome phenotype 
database, with data from the Australian Rett Syndrome Database (ARSD),[12] a population-
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based cohort, the phenotype associated with a large deletion is described in detail and 
compared with the phenotype of cases with other common mutations. 
 
METHODS 
The ARSD was established in 1993 and is a population-based register of Australian RTT 
cases born since 1976.[13] Data are collected through the submission of family and clinician 
questionnaires on recruitment.  Additional questionnaire data have been collected every two 
to three years since 2000.[14] InterRett was established in 2003[15] and cases are ascertained 
through a variety of sources including parent support groups, the listserv Rettnet and also 
bulk submission of de-identified data provided by clinicians outside Australia from countries 
such as Spain, France, Israel and Canada. InterRett questionnaires are completed online by 
families and clinicians at one time point. All cases were verified as Rett syndrome by 
fulfilling diagnostic criteria[16] and having a pathogenic MECP2 mutation. Large deletions 
were defined in this study as deletions of all or most of an exon of MECP2, occurring most 
commonly in our subjects as a deletion of all or a substantial part of exons 3 and 4. 
 
Data to describe the presence of individual aspects of phenotype including age of onset of 
common co-morbidities were available in the questionnaire responses. Data for items 
contained in the Kerr, Percy and Pineda severity scores were coded and summed to calculate 
severity scores (in which higher scores denote greater severity) as previously described.[17] 
Data from the Spanish cohort were used to calculate the Pineda scale scores but not the Kerr 
or Percy scale scores due to differences in questionnaire design (and therefore data 
collection), but were used in analyses on the individual aspects of Rett syndrome severity 




Data held in the longitudinal Australian Rett Syndrome Database were interrogated to 
describe the early developmental features, the presentation of the diagnostic criteria and the 
longitudinal course of functional abilities, scoliosis, epilepsy, sleep, behavioural and 
breathing disorders in two girls with a large deletion and to illustrate the variability in their 
phenotypes. Data were sourced from physician and family questionnaires completed at 
ascertainment to the study,[13] from follow-up family questionnaires [14 , 18]and from video 
data provided in 2004 and 2007.[19] Case study one is 10 years old; data were available from 
eight time points. Case study two is 21 years old; data were available from nine time points.  
Ethical approval for the study was provided by the ethics committee of Princess Margaret 
Hospital in Western Australia. 
 
Data analysis 
Missing data in the severity-scale individual items were imputed using Multiple Imputation 
using Chained Equations, a Stata program.[20, 21] Severity scale and item scores were 
described with standard descriptive statistics. Binary or ordinal logistic regression was used 
to assess the influence of a large deletion on individual item scores in all but the 198 Spanish 
cases. Linear regression was used to compare the presence of a large deletion with all other 
cases for each severity score. Univariate and multivariate (adjusted for the effects of age 
group (youngest) and data source (InterRett)) regression models were analysed. Time-to-
event (survival) analysis (with the median ages at onset and p values from the log-rank test of 
equivalence of survival curves) was used to investigate the risk of onset for age of features of 





At the time of data analysis a total of 974 females (746 non-Australian InterRett and 228 
from the ARSD) were eligible to be included in this study. They ranged in age from 1 year 4 
months to 49 years with a mean age of 11.53 years (median 9 years) at ascertainment or most 
recent contact where applicable. For all 974 individuals, those with a large deletion had a 
mean age of 9.14 years (median 7 years) at most recent contact and those with another 
pathogenic MECP2 mutation had a mean age of 11.66 (median 9.15 years) at most recent 
contact. Excluding the Spanish cases (n=776), those with a large deletion had a mean age of 
9.43 years (median 7 years) at most recent contact and those with another pathogenic MECP2 
mutation had a mean age of 12.46 (median 10.00 years) at most recent contact. More detailed 
genetic information was available for 43 of the 51 individuals with a large deletion and at 
least 300 base pairs were deleted from exons 3 and 4 in 22 (51.2%), exon 4 in 19 (44.2%), 
exon 1 and 2 in 1 (2.3%) and exon 2 and 3 in 1 (2.3%) of cases.  
 
The Kerr severity scores ranged from 7 to 26 points out of a possible 30, with higher scores 
denoting more severe abnormality in the common features of Rett syndrome. The average 
Kerr severity score for the 206 cases with complete information was 17.0 points and  imputed 
severity was similar for the remaining 768 cases using the Stata command MICE. The Percy 
score ranged from 7 to 36 out of a possible 45 points, with average complete-case severity of 
22.4. The Pineda score severity ranged from 6 to 26 points (maximum possible 31 points) 
with average complete-case severity of 15.99 points.  The frequency distribution by each of 
the common mutations is shown in Table 1, with the early truncating mutations including 
those nonsense mutations occurring before amino acid 310, with the exception of the 




Using the three severity scales, individuals with a large deletion had higher levels of overall 
severity compared with all other MECP2 mutations, having the highest average Pineda and 
Percy scores, and second highest average Kerr score (Table 2). Those with a large deletion 
had similar clinical severity to those with a p.R106W, p.R255X, p.R270X, early truncating 
and p.R168X mutation but were significantly more severe than those with a p.R133C, 
p.R294X, p.R306C or C-terminal deletion (Figure 1). High scores in the specific domains of 
breathing abnormalities, hand use, epilepsy, language and gross motor function contributed to 
the high severity scores. The presence of a large deletion was associated with decreased odds 
of ever having learned to walk (OR 0.42, 95%CI 0.22-0.79, p=0.007) and of currently 
walking (OR 0.53, 95%CI 0.26-1.10, p=0..089). A small proportion of those with a large 
deletion currently used words, though the proportions who had ever used babble or words 
were similar for those with and without large deletions (figure 2). Generally those with a 
large deletion were less likely than those with other mutations to have air swallowing or 
kyphosis reported (Table 3).  
 
Individuals with a large deletion were at higher odds of being in the most severe category for 
epilepsy (OR 2.72, 95%CI 1.38-5.37, p=0.004), breathing abnormalities (OR 2.19, 95% CI 
1.17 – 4.10, p=0.015), gross motor function (OR 1.84, 95%CI 0.98-3.48, p=0.057), and 
scoliosis (OR 1.81, 95% CI 0.93 – 3.49, p=0.081) after correcting for age and cohort effects. 
The severity of sleep disturbances (OR 0.90, 95% CI 0.48 – 1.71, p=0.767) and presence of 
air swallowing (OR 0.96, 95% CI 0.49 – 1.87, p=0.909) were similar between the two 




Using time-to-event (survival) analysis, those with large deletions had an earlier age of onset 
of scoliosis, seizures and abnormal breathing patterns (Figure 3).  Individuals with a large 
deletion had a median age to development of scoliosis of 6.97 years, compared with 9.44 
years for those with the other MECP2 mutations. After adjusting for cohort effects they were 
at an increased risk of developing scoliosis (HR 2.03, 95% CI 1.29 – 3.22, p=0.002)  
compared to those without large deletions. Their median age at onset of seizures was 4.00 
years compared with 5.25 years for those with other mutation types, and after adjusting for 
cohort effects, they were at an increased risk of developing seizures (HR 1.44, 95% CI 1.00 – 
2.08, p=0.050). The median age of onset of breathing abnormalities for those with a large 
deletion was 3.3 years, somewhat younger than the age of onset for those with other MECP2 
mutation types (4 years), and therefore those with large deletions were at a higher hazard of 
developing breathing abnormalities (HR 138, 95% CI 0.87– 2.21, p=0.171, adjusted for 
cohort effects). Slightly less than half (42.5%) of those with a large deletion had learned to 
walk at time of ascertainment compared with 65.5% of those with other MECP2 mutations. 
While half of the individuals with other MECP2 mutations had learned to walk by 2 years, in 
contrast, fewer than half of those with large deletions had ever learned to walk (longest 
follow up was 22 years). Consequently, those with large deletions were at a reduced hazard 
of learning to walk (HR 0.54, 95% CI 0.33 – 0.87, p=0.012). They also had a slightly earlier 
onset of hand stereotypies, with a median age of onset for those with a large deletion of 1.9 







Large Deletion Case Study 1 
This girl was born at 40 weeks gestation via caesarean section after an uneventful pregnancy. 
She rarely cried during infancy, sat at about 10 months but never learnt to roll. 
Developmental delay at 12 months led to specialist consultation. Sudden deterioration in 
speech and hand function occurred at 15 months followed by onset of hand stereotypies at 17 
months. Rett syndrome was diagnosed when she was 19 months of age. Genetic testing 
showed a deletion spanning exons 3 and 4 of the MECP2 gene. Early problems related to 
breathing disturbances and abdominal bloating, sleep disturbances with night screaming, 
teeth grinding and constipation. Scoliosis was diagnosed when she was 2 ½ years old. It 
increased progressively and surgery was conducted shortly before her 10
th
 birthday. Epilepsy 
was diagnosed at the age of  3 ½ years. It is currently managed with sodium valproate and 
lamotrigine although she still has several seizures each week. Her feeding skills declined after 
the onset of epilepsy and a gastrostomy button was later inserted for management of 
medications and to supplement oral food intake. Now 10 years old, she wakes every night, 
and often experiences anxiety and panic, screaming and laughing spells during the day or 
night. Eye gaze is her main method of communication and she has great pleasure completing 
activities with eye gaze and using a communication board. She is able to touch but not 
purposefully grasp objects and has never learned to walk. She attends a special school and 
participates in a range of therapy, music and swimming activities. 
 
Large Deletion Case Study 2  
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This girl was born by normal delivery at 35 weeks gestation. During infancy, she sat at 8 
months, rolled at 10 months, and spoke a few words at 11 months. Subsequent loss of 
communication skills occurred at 15 months, loss of hand function skills at 24 months and 
onset of stereotypies at 37 months. She learned to walk at 41 months and was diagnosed with 
Rett syndrome at 58 months with genetic testing indicating a large deletion spanning exons 3 
and 4. Epilepsy had previously developed at 32 months and throughout childhood was 
managed with sodium valproate and lamotrigine, although never completely controlled.  
Scoliosis developed at 10 ½ years of age and an anterior spinal fusion was performed at the 
age of 16 years. She has often hyperventilated and held her breath, as well as experiencing 
alterations in mood, with day and night screaming and laughing. Now 21 years of age, 
midazolam is used additionally for seizures which currently occur approximately monthly. 
Breathing abnormalities and mood alterations persist. Functional abilities have remained 
remarkably stable. She utilises eye gaze for communication. She eats more food than would 
be expected for her size, takes all food and liquids orally and mealtimes take approximately 
30 minutes. She is able to pick up and hold large and small objects, finger feed, transfer 
objects from hand to hand and can use a neat pincer grip. Mostly left-handed, she takes keen 
pleasure in placing wooden puzzles pieces into their correct position on a board and playing 
with “goop”. Late in learning to walk, she walked unsteadily but independently until 12 years 
of age after which she needed assistance to walk. Now 21 years, she can still walk with light 
support and negotiate stairs with both hands held, but often chooses to crawl for mobility 
around the house. She can also walk independently with a walking frame. She previously 
attended a mainstream school with an assistant and her program included therapies, music 
hydrotherapy and horse riding. She is currently maintaining participation in regular 





Using data from the Australian and InterRett databases, we have compared the characteristics 
of 51 individuals with a large deletion to 923 with other pathogenic MECP2 mutations. We 
have demonstrated overall that girls and women with a large deletion have the most severe 
clinical phenotype of the twelve categories of mutations examined. The variation was most 
marked for the Percy and Pineda scores which have a greater focus on developmental features 
than the Kerr score which relates more to current functioning. The early development of girls 
with a large deletion was more severely delayed with less likelihood of learning to walk. This 
severe course continued with greater severity and earlier onset of epilepsy and scoliosis than 
in those without a large deletion. 
 
Less than half of the girls with a large deletion had learned to walk compared with over two 
thirds of those with other pathogenic mutations. Moreover, only a quarter of those with a 
large deletion were still walking compared with 42% of those with other mutations. We have 
been able to demonstrate this specific impairment in gross motor function, previously 
reported in a US study (n=17 with large deletion),[9] both by using logistic regression with 
ever having walked and currently walking being treated as binary outcomes and in time to 
event analysis with learning to walk as the outcome. If unable to walk, programs of activities 
that promote the development and strengthening of abilities to maintain upright postures such 
as floor sitting, stool sitting, standing, and assisted walking as able, should be determined on 
a case by case basis. The design of gross motor opportunities for exercise and activities at all 
levels of function should promote a pro-active lifestyle aiming to protect as far as possible 




Consistent with the early gross motor impairment  we also noted that a much higher 
proportion of those with large deletions never developed or completely lost hand function 
compared to those with other mutations, where a higher proportion had conserved or partially 
conserved hand function. One characteristic feature of the regression period in Rett syndrome 
is the development of hand stereotypies.  Time to event analysis showed that those with large 
deletions were likely to have a slightly earlier development of hand stereotypies than those 
without. In addition to gross motor and hand function the other core feature affected by Rett 
syndrome is language development. There, we found that a higher proportion of those with 
large deletions either had no speech or only babbling as opposed to single words or preserved 
speech compared to those without a large deletion. 
 
Two of the major co-morbidities in Rett syndrome are scoliosis and seizures. We previously 
found that in the Australian cohort the median age of onset of scoliosis was 9.8 years.[23] 
This was a similar age (9.4 years) to what we found in this study for those with other 
pathogenic mutations. However for those with a large deletion the median age of onset was 
much younger at 7.0 years. This might be expected given the high proportion that did not 
learn to walk and the known association between never walking and an earlier age of 
scoliosis onset.[23, 24]  Similar to scoliosis we found an earlier age of seizure onset in those 
with large deletions (median age of 48 months) than in those without (median age of 61 
months).  In a previous Australian study, the median age at onset of seizures among the 
MECP2 mutation groups varied from 37 months in those with a p.R255X mutation to 76 
months in cases with the p.R294X mutation and was 42 months for those with a large 
deletion. [25] Few studies have examined the relationship between genotype and seizure 
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severity.  In another Australian study using data collected in 2000, the seizure rate in those 
with a C terminal deletions and in those with a p.R294X mutation was significantly lower 
than  in those with no identified mutation.[26] In a more recent Italian [27] but not in a US 
study,[28] this result was replicated for C terminal deletions but not for p.294X mutations. In 
the 2000 Australian study we were not able to demonstrate an increased seizure rate in those 
with large deletions, but only five individuals with a large deletion were included. [26] 
However in the present study of 51 individuals, those with a large deletion were at greater 
odds than those with another pathogenic mutation of having epilepsy of earlier onset and 
greater severity. Similarly, in the Italian study seizures had occurred in 9/10 of those with 
large deletions while in the US study[28] the p.T158M mutation was the mutation where 
seizures were reported most frequently. 
 
Other morbidities such as sleep problems and breathing abnormalities have been studied even 
less than seizures in relation to genotype. In a previous Australian study we found that a high 
prevalence of reported sleep problems and night laughing did appear to be commoner in those 
with a large deletion.[29] However the number of large deletion cases was only five. 
Although both individuals in the case studies experienced night laughing, we weren’t able to 
systematically examine this in the present study and were unable to replicate our previous 
findings relating to sleep problems. There is also scant research on relationships between 
breathing abnormalities and genotype, and this is an area requiring further research.   
 
Although individual studies are showing variation in relation to the effect of genotype on co-
morbidities such as seizures, the only other large study that has examined overall severity 
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also found that large deletions had a severe phenotype second only to the mutation 
p.R168X.[9] This study also found, as we did, that higher proportions of individuals with 
large deletions were more impaired in the core domains of ambulation, hand use and 
language. In the current study, the clinical presentations observed in those with a large 
deletion were similarly severe to those with the early truncating mutations including 
p.R168X, p.R255X and p.R270X. This could relate to greater loss of MeCP2 including loss 
of function in the transcriptional repressor domain and nuclear localization signal areas 
compared with other mutations such as p.R133C, p.R306C, p.R294X or the C-terminal 
deletions where these areas are less disrupted. Whereas the latter mutations have been 
associated with milder presentations. early truncating mutations have been associated with 
greater severity.[9, 10, 30] Whilst all of the MeCP2 structural domains are necessary to 
mediate normal cellular actions of MeCP2,[31] it is possible that areas of the central nervous 
system are differentially susceptible than others to the degree of dysfunction in MeCP2 
protein. A less functional protein with greater loss of genetic material could be more 
disruptive to brainstem and cerebellar structures than a more functional protein,[32]and may 
account for phenotypic differences such as muscle tone and motor function. 
 
Despite the overall severity, as with many of the MECP2 mutation groupings there is clearly 
considerable variation which could account for the differing results, for example, in relation 
to epilepsy. This is the reason why we elected to present two case vignettes, both of whom 
had a large deletion spanning sections of exons 3 and 4, to demonstrate the contrasting 
phenotypes which may result from a large deletion. The first individual is clearly very severe 
and demonstrates well what might be expected in the phenotype of a large deletion: lack of 
ambulation, early regression, lack of purposeful hand function and early onset of both 
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seizures and scoliosis. The second case study demonstrates milder symptoms. She learned to 
walk late, has had and is maintaining hand function at a level 8,[33] is able to crawl and use a 
Zimmer frame independently and eats well orally. Her functional abilities remain generally 
strong now she is a young woman and her overall presentation is quite different from the 
expected phenotype. Despite this she had relatively early onset of seizures and required 
surgical correction of scoliosis. It was only the large deletion category which was examined 
in the US study in relation to X-inactivation[9] and it found that there was indeed a 
relationship between skewing and the ability to walk in these individuals. Such a mechanism 
could also account for our findings in this young woman. 
 
We acknowledge that factors such as X inactivation [34] or BDNF status [35] could influence 
the MECP2 mutation and that this genetic information would be a useful supplement to our 
analysis. We also recognise that the size of the deletion is variable among individuals and 
suggest that this be analysed in the future. Whilst the ARSD is population-based, the 
InterRett database is not and the cases ascertained from this database may be subject to 
selection bias and possibly not fully represent the variability associated with the mutation. On 
the other hand, in our study the combination of the resources of the two databases has 
allowed us to accumulate 51 individuals with a large deletion. To our knowledge, this is the 
largest study to date to describe this mutation and the sample size has allowed use of 
appropriate statistical methods including survival analysis. Our case studies also use 
information collected at multiple time points[14] and questionnaire data has been 
supplemented with observed video data of functional abilities that had been collected on two 
occasions.[19, 33, 36] Longitudinal data from different perspectives was able to provide 
depth to the description of our case studies.  
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Testing for a large deletion on the MECP2 gene is now widely available and has allowed 
genetic confirmation of a Rett syndrome diagnosis for such individuals. Our study 
complements previous smaller studies.  For clinicians, we have provided a disorder profile 
based on the largest dataset of cases with a large deletion thus far and although some 
individuals have milder presentations, the clinical picture is generally severe. This better 
understanding of the phenotype could assist with counselling and planning of management 
strategies to address clinical needs. Further research should follow the cohort over time to 
identify long term trajectories more clearly. 
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Table 1: Frequency distribution for each category of pathogenic mutation for each data 





































































































Table 2: Univariate and multivariate relationships calculated with linear regression between 











(95% CI) p-value 
Adjusted mean 





























































Table 3: Univariate and multivariate results of binary logistic regression analysis of 
















P-value (95% CI) (95% CI) 
Ever walked 










0.076 (0.20 - 0.71) (0.22- 0.79) 
Currently 
walking 










0.089 (0.24 - 1.01) (0.26 - 1.10) 
Ever talked 










0.215 (0.32 - 1.16) (0.34 - 1.27) 
Ever had 
hand use 










0.404 (0.24 - 1.72) (0.24 - 1.77) 
Maintained 
hand use 










0.079 (0.22 - 1.29) (0.16 - 1.10 
Air 
swallowing 










0.636 (0.40 - 1.47) (0.44 - 1.65) 
Kyphosis 










(0.04 - 2.07) 
0.21 
0.38 
(0.05 - 2.98) 
0.358 
1 
For the factor “currently talking”, there were no cases with a large deletion able to talk in 
comparison with 21 (3.1%) of all other cases and unable to analyse because of zero 
frequencies; 
2 
adjusting for age and data source 
23 
 
Figure 1: Mean and 95% confidence interval values for each severity score for each category 








Figure 2: Proportions of individuals with a large deletion or other common mutation for each 
level of severity in selected items from each of the severity scales. Scoliosis and air 











Figure 3: Kaplan-Meier survival estimate of time to age of onset of scoliosis, seizures, ability 
to walk and abnormal breathing in individuals with and without a large deletion 
 
 
